Hiscox S - Search Results

1

Zinc transporter LIV-1: a link between cellular development and cancer progression.

Taylor KM, Hiscox S, Nicholson RI. Taylor KM, et al. Among authors: hiscox s. Trends Endocrinol Metab. 2004 Dec;15(10):461-3. doi: 10.1016/j.tem.2004.10.003. Trends Endocrinol Metab. 2004. PMID: 15541644

2

Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination.

Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, Hiscox SE, Barrow D, Gee JM. Nicholson RI, et al. Clin Cancer Res. 2004 Jan 1;10(1 Pt 2):346S-54S. doi: 10.1158/1078-0432.ccr-031206. Clin Cancer Res. 2004. PMID: 14734490

3

Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839).

Hiscox S, Morgan L, Barrow D, Dutkowskil C, Wakeling A, Nicholson RI. Hiscox S, et al. Clin Exp Metastasis. 2004;21(3):201-12. doi: 10.1023/b:clin.0000037697.76011.1d. Clin Exp Metastasis. 2004. PMID: 15387370

4

Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells.

Jones HE, Goddard L, Gee JM, Hiscox S, Rubini M, Barrow D, Knowlden JM, Williams S, Wakeling AE, Nicholson RI. Jones HE, et al. Among authors: hiscox s. Endocr Relat Cancer. 2004 Dec;11(4):793-814. doi: 10.1677/erc.1.00799. Endocr Relat Cancer. 2004. PMID: 15613453

5

Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies.

Nicholson RI, Hutcheson IR, Britton D, Knowlden JM, Jones HE, Harper ME, Hiscox SE, Barrow D, Gee JM. Nicholson RI, et al. Among authors: hiscox se. J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):257-62. doi: 10.1016/j.jsbmb.2004.12.006. Epub 2005 Feb 8. J Steroid Biochem Mol Biol. 2005. PMID: 15860268 Review.

6

Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation.

Hiscox S, Jiang WG, Obermeier K, Taylor K, Morgan L, Burmi R, Barrow D, Nicholson RI. Hiscox S, et al. Int J Cancer. 2006 Jan 15;118(2):290-301. doi: 10.1002/ijc.21355. Int J Cancer. 2006. PMID: 16080193

7

Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer.

Nicholson RI, Hutcheson IR, Hiscox SE, Knowlden JM, Giles M, Barrow D, Gee JM. Nicholson RI, et al. Among authors: hiscox se. Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S29-36. doi: 10.1677/erc.1.00991. Endocr Relat Cancer. 2005. PMID: 16113097 Review.

8

Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.

Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI. Hiscox S, et al. Breast Cancer Res Treat. 2006 Jun;97(3):263-74. doi: 10.1007/s10549-005-9120-9. Epub 2005 Dec 7. Breast Cancer Res Treat. 2006. PMID: 16333527

9

Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions.

Hiscox S, Jordan NJ, Jiang W, Harper M, McClelland R, Smith C, Nicholson RI. Hiscox S, et al. Endocr Relat Cancer. 2006 Dec;13(4):1085-99. doi: 10.1677/erc.1.01270. Endocr Relat Cancer. 2006. PMID: 17158755

10

Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer.

Hiscox S, Morgan L, Green T, Nicholson RI. Hiscox S, et al. Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S53-9. doi: 10.1677/erc.1.01297. Endocr Relat Cancer. 2006. PMID: 17259559 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

89 results

Search Page

Filters